Neurodegenerative disease: Taming the RAGE of Alzheimer's disease

Nature Reviews Drug Discovery

Volumn 11, Issue 5, 2012, Pages 351-

  Crunkhorn, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR INHIBITOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; FPS ZM1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOOTROPIC AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; BLOOD BRAIN BARRIER; COGNITION; DEMENTIA; DRUG SYNTHESIS; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 84860359366     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3727     Document Type: Note

References (1)

1. Deane, R. et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122, 1377-1392 (2012)